X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2020) 2020
Publication (195) 195
Newspaper Article (69) 69
Book Review (19) 19
Book Chapter (14) 14
Trade Publication Article (7) 7
Book / eBook (4) 4
Magazine Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1534) 1534
oncology (1136) 1136
index medicus (1039) 1039
female (1025) 1025
chemotherapy (950) 950
consolidation (891) 891
male (881) 881
middle aged (865) 865
hematology (827) 827
adult (805) 805
antineoplastic combined chemotherapy protocols - therapeutic use (694) 694
aged (615) 615
cancer (571) 571
treatment outcome (540) 540
consolidation chemotherapy (490) 490
consolidation therapy (412) 412
remission induction (408) 408
disease-free survival (399) 399
adolescent (395) 395
therapy (334) 334
survival (303) 303
transplantation (293) 293
prognosis (285) 285
care and treatment (267) 267
combined modality therapy (264) 264
survival analysis (258) 258
young adult (242) 242
stem-cell transplantation (240) 240
trial (237) 237
acute myelogenous leukemia (228) 228
antineoplastic combined chemotherapy protocols - adverse effects (228) 228
retrospective studies (223) 223
survival rate (223) 223
radiotherapy (219) 219
neoplasm staging (212) 212
follow-up studies (206) 206
leukemia (204) 204
patients (200) 200
cytarabine - administration & dosage (196) 196
leukemia, myeloid, acute - drug therapy (192) 192
antineoplastic agents - therapeutic use (188) 188
hematopoietic stem cell transplantation (186) 186
induction chemotherapy (186) 186
acute myeloid-leukemia (185) 185
acute myeloid leukemia (184) 184
antineoplastic combined chemotherapy protocols - administration & dosage (183) 183
hematology, oncology and palliative medicine (180) 180
transplantation, autologous (179) 179
stem cells (175) 175
remission (173) 173
medicine & public health (170) 170
risk factors (170) 170
aged, 80 and over (166) 166
recurrence (166) 166
child (165) 165
research (165) 165
induction (152) 152
cytarabine (151) 151
cisplatin (146) 146
health aspects (146) 146
stem cell transplantation (142) 142
child, preschool (141) 141
analysis (139) 139
clinical trials (138) 138
bone-marrow-transplantation (135) 135
chemoradiotherapy (128) 128
trans-retinoic acid (128) 128
lymphomas (126) 126
consolidation chemotherapy - methods (124) 124
leukemia, promyelocytic, acute - drug therapy (123) 123
risk (122) 122
immunology (121) 121
multiple myeloma (120) 120
adults (118) 118
bone-marrow transplantation (117) 117
leukemia, myeloid, acute - mortality (117) 117
leukemia, myeloid, acute - therapy (115) 115
ovarian cancer (115) 115
high-dose chemotherapy (114) 114
relapse (114) 114
bortezomib (110) 110
carboplatin (110) 110
randomized-trial (110) 110
cyclophosphamide (109) 109
children (108) 108
aml (106) 106
cyclophosphamide - administration & dosage (105) 105
infant (104) 104
medicine, general & internal (104) 104
acute nonlymphocytic leukemia (103) 103
diagnosis (103) 103
prospective studies (103) 103
maintenance chemotherapy (102) 102
minimal residual disease (102) 102
daunorubicin (100) 100
acute promyelocytic leukemia (99) 99
drug therapy (97) 97
toxicity (97) 97
etoposide - administration & dosage (95) 95
drug administration schedule (94) 94
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2036) 2036
French (18) 18
Japanese (13) 13
German (11) 11
Russian (10) 10
Chinese (7) 7
Spanish (7) 7
Korean (6) 6
Polish (2) 2
Czech (1) 1
Hungarian (1) 1
Persian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet Oncology, ISSN 1470-2045, 08/2017, Volume 18, Issue 8, pp. 1076 - 1088
The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated... 
CLINICAL-PRACTICE GUIDELINES | SURVIVAL | SUPPORT | IMPACT | CONSOLIDATION | RESPONSE CRITERIA | ONCOLOGY | R-CHOP | NON-HODGKIN-LYMPHOMA | ELDERLY-PATIENTS | MEGACHOEP | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Mitoxantrone - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Transplantation, Autologous | Consolidation Chemotherapy | Cyclophosphamide - adverse effects | Lymphoma, Large B-Cell, Diffuse - therapy | Vincristine - administration & dosage | Adult | Female | Doxorubicin - administration & dosage | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Prednisone - adverse effects | Risk Factors | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Melphalan - administration & dosage | Intention to Treat Analysis | Vincristine - adverse effects | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Carmustine - administration & dosage | Stem Cell Transplantation - adverse effects | Stem cells
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 01/2014, Volume 61, Issue 1, pp. 95 - 101
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 874 - 885
Summary Background Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined.... 
Hematology, Oncology and Palliative Medicine | MAINTENANCE | SUPERIORITY | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | IMPACT | METAANALYSIS | ONCOLOGY | CLINICAL-TRIALS | LENALIDOMIDE | SALVAGE THERAPY | INDUCTION | MARROW TRANSPLANTATION | Recurrence | Cyclophosphamide - administration & dosage | Peripheral Nervous System Diseases - chemically induced | Consolidation Chemotherapy - methods | Humans | Middle Aged | Pyrazines - administration & dosage | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Multiple Myeloma - therapy | Time Factors | Adult | Female | Boronic Acids - administration & dosage | Neutropenia - chemically induced | Doxorubicin - administration & dosage | Bortezomib | Dexamethasone - administration & dosage | Proportional Hazards Models | Thrombocytopenia - chemically induced | Disease Progression | Induction Chemotherapy - adverse effects | Retreatment | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged | Multiple Myeloma - genetics | Stem Cell Transplantation - adverse effects | Care and treatment | Relapse | Multiple myeloma | Clinical trials | Transplantation | Diseases | Cyclophosphamide | Chemotherapy | Hospitals | Stem cells | Dosage and administration | Product development | Cancer
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 06/2014, Volume 61, Issue 6, pp. 977 - 981
ABSTRACT Background To evaluate long‐term survival of the first cohort of stage‐4 neuroblastoma patients treated with the N7 induction chemotherapy, surgery of... 
Busulphan–Melphalan | neuroblastoma | high‐dose chemotherapy | Busulphan-Melphalan | High-dose chemotherapy | Neuroblastoma | STAGE-4 NEUROBLASTOMA | BONE-MARROW-TRANSPLANTATION | 13-CIS-RETINOIC ACID | RANDOMIZED-TRIAL | ONCOLOGY | PEDIATRICS | HIGH-RISK NEUROBLASTOMA | STEM-CELL TRANSPLANTATION | OF-PEDIATRIC-ONCOLOGY | MULTIVARIATE-ANALYSIS | CHILDREN OLDER | HEMATOLOGY | high-dose chemotherapy | AGE | Myeloablative Agonists - therapeutic use | Follow-Up Studies | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Transplantation, Autologous | Consolidation Chemotherapy | Genes, myc | Busulfan - administration & dosage | Neuroblastoma - secondary | Child | Abdominal Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Combined Modality Therapy | Remission Induction | Abdominal Neoplasms - surgery | Thoracic Neoplasms - surgery | Hepatic Veno-Occlusive Disease - chemically induced | Disease-Free Survival | Melphalan - administration & dosage | Gene Amplification | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neuroblastoma - drug therapy | Neuroblastoma - surgery | Thoracic Neoplasms - drug therapy | Transplantation Conditioning | Stem cells | Melphalan | Busulfan | Index Medicus
Journal Article
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 111 - 121
Journal Article
by Bujko, K and Wyrwicz, L and Rutkowski, A and Malinowska, M and Pietrzak, L and Kryński, J and Michalski, W and Oledzki, J and Kuśnierz, J and Zajac, L and Bednarczyk, M and Szczepkowski, M and Tarnowski, W and Kosakowska, E and Zwoliński, J and Winiarek, M and Wiśniowska, K and Partycki, M and Beczkowska, K and Polkowski, W and Styliński, R and Wierzbicki, R and Bury, P and Jankiewicz, M and Paprota, K and Lewicka, M and Ciseł, B and Skórzewska, M and Mielko, J and Bebenek, M and Maciejczyk, A and Kapturkiewicz, B and Dybko, A and Hajac, Ł and Wojnar, A and Leśniak, T and Zygulska, J and Jantner, D and Chudyba, E and Zegarski, W and Las-Jankowska, M and Jankowski, M and Kołodziejski, L and Radkowski, A and Zelazowska-Omiotek, U and Czeremszyńska, B and Kepka, L and Kolb-Sielecki, J and Toczko, Z and Fedorowicz, Z and Dziki, A and Danek, A and Nawrocki, G and Sopyło, R and Markiewicz, W and Kedzierawski, P and Wydmański, J and Albinski, J and Banaś, R and Chmielowska, E and Bal, W and Baszczyk-Mnich, J and Bialas, M and Borowiec, T and Bujko, M and Cencelewicz, A and Chomik, K and Chwalinski, M and Ciepela, I and Dupla, D and Florek, A and Górnicki, A and Jeziorski, K and Józwickil, W and Kobiela, J and Koda, M and Kolodziej, P and Kruszewski, P and Kryj, M and Kuciel-Lisiecka, G and Kwiatkowski, R and Lachowski, A and Liszka-Dalecki, P and Majewski, A and Majewski, W and Majsak, T and Maka, D and Malka, M and Mazurkiewicz, A and Morawiec, J and Nogal, E and Olejniczak, M and Olkowski, D and Ostrowska-Cichocka, K and Pietruszka, M and Piotrkowski, G and Plewicka, M and Porzuczek-Zuziak, D and Reszke, J and Rychter, A and ... and Polish Colorectal Study Group
Annals of Oncology, ISSN 0923-7534, 05/2016, Volume 27, Issue 5, pp. 834 - 842
Journal Article